Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) develops, manufactures, and distributes orthopedic reconstructive products, sports medicine, trauma products, spine, craniomaxillofacial, and thoracic (CMFT) products, and other dental implants. ZBH products and treatments aid in treating patients with bone, joint, or supporting soft tissue illnesses or injuries.
Why should Investors make an Exit?
- Long Cash Conversion Cycle: The company's cash conversion days were 392.2 days at the end of December 31, 2021, compared to the industry median of 172.9 days, showing that it takes a long time to convert its inventory to cash.
- Leveraged Balance Sheet: As of December 31, 2021, the company's debt/equity ratio was 0.56x, compared to the industry median of 0.32x. Furthermore, its long-term debt-to-total-capital ratio was 27.7%, compared to 18.9% for the industry during the same period. As a result, the company's exposure to balance-sheet risk has increased.
- Deteriorating FY22 Outlook: In its full-year FY21 press release, ZBH forecasts a revenue decline of 0.00 - 4.0% YoY and adjusted diluted EPS of USD 6.40 - 6.80 for FY22. In FY21, the company reported an adjusted diluted EPS of USD 7.37. The decline in the FY22 outlook may hamper the potential interest of the shareholder's in the business.
Valuation Methodology: Price/Earnings Per Share Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
ZBH's share price has been volatile throughout the year, surged 12.22% in the past month and is currently leaning towards the mid-band of its 52-week range of USD 105.23 to USD 175.97. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 63.98, approaching the overbought zone. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 114.30.
Considering the current trading levels, long cash conversion days, dwindling FY22 outlook, current valuation, and other technical indicators, we recommend a "Sell" rating on the stock at the closing price of USD 129.91, up 1.61% as of April 07, 2022.
Three-Year Technical Price Chart (as of April 07, 2022). Source: REFINITIV, Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.